Last reviewed · How we verify
AZT+3TC+IDV+RTV
This combination inhibits HIV reverse transcriptase and protease to suppress viral replication.
This combination antiretroviral regimen inhibits HIV replication by blocking reverse transcriptase and protease enzymes simultaneously. Used for HIV-1 infection.
At a glance
| Generic name | AZT+3TC+IDV+RTV |
|---|---|
| Sponsor | Hospital Clinic of Barcelona |
| Drug class | Antiretroviral combination therapy (NRTI + PI) |
| Target | HIV reverse transcriptase; HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
AZT and 3TC are nucleoside reverse transcriptase inhibitors (NRTIs) that block the enzyme responsible for converting HIV RNA into DNA. IDV and RTV are protease inhibitors that prevent the cleavage of viral polyproteins, blocking the maturation of infectious viral particles. Together, this quadruple therapy targets two critical steps in the HIV replication cycle.
Approved indications
- HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Lipodystrophy
- Hyperglycemia
- Hepatotoxicity
- Peripheral neuropathy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Prospective Cohort of Children With HIV Infection
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs (PHASE2)
- A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART
- A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection (NA)
- A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure (PHASE2)
- HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZT+3TC+IDV+RTV CI brief — competitive landscape report
- AZT+3TC+IDV+RTV updates RSS · CI watch RSS
- Hospital Clinic of Barcelona portfolio CI